In the available data, all ICI-related regimens had significant vitiligo signals, and anti-PD-1/L1 combined with anti-CTLA-4 therapy showed the strongest signal (ROR: 55.89; 95% CI: 42.34–73.78; IC025: 4.73). This evidence concerns the gene CTLA4 and vitiligo.